Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

February 26, 2025
Alfresa Holdings Corporation

Notice regarding Cancellation of Treasury Shares (Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act of Japan)

Alfresa Holdings Corporation hereby announces that, at a meeting of its Board of Directors held on February 26, 2025, it resolved to cancel a portion of its treasury shares pursuant to Article 178 of the Companies Act of Japan, as outlined below.

1.	Type of shares to be canceled	Common stock
2.	Number of shares to be canceled	11,540,000 shares (5.7% of the number of outstanding shares before cancellation)
3.	Date of cancellation	March 14, 2025

(Reference)

Number of outstanding shares after cancellation	191,300,000 shares
Number of treasury shares before cancellation*	21,051,186 shares

* As of February 21, 2025. It includes the Company's 414,832 shares held by the Board Incentive Plan (BIP) trust account for officers' compensation.

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, "we create and deliver a fresh life for all," come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥2.8 trillion for the fiscal year ended March 31, 2024. For more information, please see: https://www.alfresa.com/eng/